LRRK2 Parkinson's disease: From animal models to cellular mechanisms

Reviews in the Neurosciences

Volumn 22, Issue 4, 2011, Pages 411-418

  Lin, Chin Hsien ^a,b   Tsai, Pei I ^a   Wu, Ruey Meei ^b   Chin, Cheng Ting ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

animal models; LRRK2; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

GENE MUTATION; HUMAN; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 80051707484     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/RNS.2011.036     Document Type: Review

References (56)

1. Andres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B.M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L., et al. (2009). Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine). J. Neurosci. 29, 15846-15850.
2. Braak, H. and Del Tredici, K. (2008). Invited article: Nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916-1925. (Pubitemid 351684646)
3. Braak, H., Bohl, J.R., Muller, C.M., Rub, U., de Vos, R.A., and Del Tredici, K. (2006). Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21, 2042-2051. (Pubitemid 46140410)
4. Chaudhuri, K.R., Healy, D.G., and Schapira, A.H. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol. 5, 235-245.
5. de Lau, L.M. and Breteler, M.M. (2006). Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535. (Pubitemid 44262284)
6. Di Fonzo, A., Rohe, C.F., Ferreira, J., Chien, H.F., Vacca, L., Stocchi, F., Guedes, L., Fabrizio, E., Manfredi, M., Vanacore, N., et al., Italian Parkinson Genetics Network. (2005). A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365, 412-415. (Pubitemid 40179228)
7. Farrer, M., Stone, J., Mata, I.F., Lincoln, S., Kachergus, J., Hulihan, M., Strain, K.J., and Maraganore, D.M. (2005). LRRK2 mutations in Parkinson disease. Neurology 65, 738-740. (Pubitemid 41285854)
8. Farrer, M.J., Stone, J.T., Lin, C.H., Dächsel, J.C., Hulihan, M.M., Haugarvoll, K., Ross, O.A., and Wu, R.M. (2007). Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat. Disord. 13, 89-92. (Pubitemid 46329522)
9. Gandhi, P.N., Wang, X., Zhu, X., Chen, S.G., and Wilson-Delfosse, A.L. (2008). The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86, 1711-1720. (Pubitemid 351859422)
10. Gehrke, S., Imai, Y., Sokol, N., and Lu, B. (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641.
11. Gillardon, F. (2009). Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110, 1514-1522.
12. Gloeckner, C.J., Kinkl, N., Schumacher, A., Braun, R.J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H., Ueffing, M. (2006). The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232. (Pubitemid 43125977)
13. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J., et al. (2006). Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341. (Pubitemid 44097032)
14. Guo, L., Gandhi, P.N., Wang, W., Petersen, R.B., Wilson-Delfosse, A.L., and Chen, S.G. (2007). The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 313, 3658-3670. (Pubitemid 47404550)
15. Haghighat, A., Mader, S., Pause, A., and Sonenberg, N. (1995). Repression of cap-dependent translation by 4E-binding protein 1: Competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 14, 5701-5709.
16. Hatano, T., Kubo, S., Sato, S., and Hattori, N. (2009). Pathogenesis of familial Parkinson's disease: New insights based on monogenic forms of Parkinson's disease. J. Neurochem. 111, 1075-1093.
17. Hirao, M., Sato, N., Kondo, T., Yonemura, S., Monden, M., Sasaki, T., Takai, Y., Tsukitas, S., and Tsukitas, S. (1996). Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: Possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J. Cell Biol. 135, 37-51. (Pubitemid 26337735)
18. Ho, C.C., Rideout, H.J., Ribe, E., Troy, C.M., and Dauer, W.T. (2009). The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci. 29, 1011-1016.
19. Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carri, M.T., and Barone P. (2007). Apoptotic mechanisms in mutant LRRK2- mediated cell death. Hum. Mol. Genet. 16, 1319-1326. (Pubitemid 47055127)
20. Imai, Y., Gehrke, S., Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E., and Lu, B. (2008). Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432-2443.
21. Ishihara, L., Warren, L., Gibson, R., Amouri, R., Lesage, S., Dürr, A., Tazir, M., Wszolek, Z.K., Uitti, R.J., Nichols, W.C., et al. (2006). Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch. Neurol. 63, 1250-1254. (Pubitemid 44379825)
22. Kapahi, P., Chen, D., Rogers, A.N., Katewa, S.D., Li, P.W., Thomas, E.L., and Kockel, L. (2010). With TOR, less is more: A key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 11, 453-465.
23. Korr, D., Toschi, L., Donner, P., Pohlenz, H.D., Kreft, B., and Weiss, B. (2006). LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell. Signal. 18, 910-920. (Pubitemid 43210446)
24. Lee, S.B., Kim, W., Lee, S., and Chung, J. (2007). Loss of LRRK2/ PARK8 induces degeneration of dopaminergic neurons in Drosophila Biochem. Biophys. Res. Commun. 358, 534-539. (Pubitemid 46755736)
25. Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L., West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers, W.J., Federoff, H.J., et al. (2010a). Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 16, 998-1000.
26. Lee, S., Liu, H.P., Lin, W.Y., Guo, H., and Lu, B. (2010b). LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Droso phila neuromuscular junction. J. Neurosci. 30, 16959-16969.
27. Lesage, S., Ibanez, P., Lohmann, E., et al. (2005). G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58, 784-787. (Pubitemid 41552556)
28. Lesage, S., Durr, A., Tazir, M., Pollak, P., Tison, F., Tazir, M., Leutenegger, A.L., Guimaraes, J., Bonnet, A.M., Agid, Y., et al., French Parkinson's Disease Genetics Study Group. (2006). LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422-423. (Pubitemid 43145082)
29. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A., and Cookson, M.R. (2007). The R1441C mutation of disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671. (Pubitemid 46653831)
30. Li, Y., Liu, W., Oo, T.F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., et al. (2009). Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826-828.
31. Li, X., Patel, J.C., Wang, J., Avshalumov, M.V., Nicholson, C., Buxbaum, J.D., Elder, G.A., Rice, M.E., and Yue, Z. (2010). Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 30, 1788-1797.
32. Lin, C.H., Tzen, K.Y., Yu, C.Y., Tai, C.H., Farrer, M.J., and Wu, R.M. (2008). LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: Clinical, PET, and functional studies. J. Biomed. Sci. 15, 661-667.
33. Lin, X., Parisiadou, L., Gu, X.L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.X., Yang, W.J., Ding, J., et al. (2009). Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease- related mutant alpha-synuclein. Neuron 64, 807-827.
34. Lin, C.H., Tsai, P.I., Wu, R.M., and Chien, C.T. (2010). LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J. Neurosci. 30, 13138-13149.
35. Liu, Z., Wang, X., Yu, Y., Li, X., Wang, T., Jiang, H., Ren, Q., Jiao, Y., Sawa, A., Moran, T., et al. (2008). A Drosophila model for LRRK2-linked parkinsonism. Proc. Natl. Acad. Sci. USA. 105, 2693-2698. (Pubitemid 351520575)
36. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., and Abeliovich, A. (2006). The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593. (Pubitemid 44781171)
37. Marin, I. (2006). The Parkinson disease gene LRRK2: Evolutionary and structural insights. Mol. Biol. Evol. 23, 2423-2433. (Pubitemid 44737136)
38. Nichols, W.C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C.A., Michaels, V.E., Reed, T., Rudolph, A., et al., Parkinson Study Group-PROGENI Investigators. (2005). Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365, 410-412. (Pubitemid 40179227)
39. Nolano, M., Provitera, V., Estraneo, A., Selim, M.M., Caporaso, G., Stancanelli, A., Saltalamacchia, A.M., Lanzillo, B., and Santoro, L. (2008). Sensory deficit in Parkinson's disease: Evidence of a cutaneous denervation. Brain 131 (Pt 7), 1903-1911. (Pubitemid 351957457)
40. Ozelius, L.J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A.L., Klein, C., Henick, B., Hailpern, S.M., et al. (2006). LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424-425. (Pubitemid 43145083)
41. Paisán-Ruíz, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., van der Brug, M., López de Munain, A., Aparicio, S., Gil, A.M., Khan, N., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600. (Pubitemid 39531224)
42. Parisiadou, L., Xie, C., Cho, H.J., Lin, X., Gu, X.L., Long, C.X., Lobbestael, E., Baekelandt, V., Taymans, J.M., Sun, L., et al. (2009). Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 29, 13971-13980.
43. Plowey, E.D., Cherra, S.J. 3rd, Liu, Y.J., and Chu, C.T. (2008). Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 105, 1048-1056. (Pubitemid 351565713)
44. Ross, O.A., Wu, Y.R., Lee, M.C., Funayama, M., Chen, M.L., Soto, A.I., Mata, I.F., Lee-Chen, G.J., Chen, C.M., Tang, M., et al. (2008). Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64, 88-92.
45. Saha, S., Guillily, M.D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C.H., Segal, L., Raghavan, K., Matsumoto, K., et al. (2009). LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans J. Neurosci. 29, 9210-9218.
46. Sakaguchi-Nakashima, A., Meir, J.Y., Jin, Y., Matsumoto, K., and Hisamoto, N. (2007). LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol. 17, 592-598. (Pubitemid 46497793)
47. Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M., Ross, C.A., et al. (2005). Leucinerich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. USA 102, 18676-18681. (Pubitemid 43011285)
48. Tain, L.S., Mortiboys, H., Tao, R.N., Ziviani, E., Bandmann, O., and Whitworth, A.J. (2009). Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12, 1129-1135.
49. Tan, E.K., Peng, R., Teo, Y.Y., Tan, L.C., Angeles, D., Ho, P., Chen, M.L., Lin, C.H., Mao, X.Y., Chang, X.L., et al. (2010). Multiple LRRK2 variants modulate risk of Parkinson disease: A Chinese multicenter study. Hum. Mutat. 31, 561-568.
50. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E.N., and Shen, J. (2009). R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. USA 106, 14622-14627.
51. Venderova, K., Kabbach, G., Abdel-Messih, E., Zhang, Y., Parks, R.J., Imai, Y., Gehrke, S., Ngsee, J., Lavoie, M.J., Slack, R.S., et al. (2009). Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum. Mol. Genet. 18, 4390-4404.
52. Webber, P.J. and West, A.B. (2009). LRRK2 in Parkinson's disease: Function in cells and neurodegeneration. FEBS J. 276, 6436-6444.
53. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., Dawson, T.M. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102, 16842-16847. (Pubitemid 41688864)
54. Westerlund, M., Belin, A.C., Anvret, A., Bickford, P., Olson, L., and Galter, D. (2008). Developmental regulation of leucinerich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 152, 429-436.
55. Wolozin, B., Saha, S., Guillily, M., Ferree, A., and Riley, M. (2008). Investigating convergent actions of genes linked to familial Parkinson's disease. Neurodegener. Dis. 5 (3-4), 182-185. (Pubitemid 351347845)
56. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607. (Pubitemid 39531225)